Jump to content

Drilldown: Medicines

Pharmacopedia is being built in public. Pages may be incomplete.About this site

Choose a table:


Medicines > classes : Cathinone or Empathogen or [[:Category:Antihistamines|Antihistamine]]

Use the filters below to narrow your results.

classes: (Click arrow to add another value)
mechanism:
Cathinone analogue; monoamine reuptake inhibitor (2) · MAO inhibitor; monoamine releasing agent (1) · MAO inhibitor; serotonin releasing agent (1) · Monoamine releasing agent (5) · Monoamine releasing agent; 5-HT2A agonist (1) · Monoamine releasing agent; active ingredient in khat (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Serotonin releasing agent (2) · Serotonin releasing agent; 5-HT2A agonist (3) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · '"`UNIQ--vote-00000391-QINU`"' Minimal CYP metabolism; mostly renally cleared unchanged. Cetirizine is the active racemate; levocetirizine is the active R-enantiomer marketed separately'"`UNIQ--ref-00000392-QINU`"'. (1) · '"`UNIQ--vote-0000061E-QINU`"' Less reliably anticholinergic than first-generation H1s; minimal antiemetic effect. Desloratadine (Clarinex) is the active enantiomer-of-metabolite version marketed as a Rx alternative. (1) · '"`UNIQ--vote-00000950-QINU`"' Mostly renally cleared unchanged; dose-reduce in renal impairment. Like cetirizine, retains slightly more sedation than fexofenadine in some users'"`UNIQ--ref-00000951-QINU`"'. (1) · '"`UNIQ--vote-00000CC9-QINU`"' Mostly excreted unchanged in feces and urine; P-glycoprotein substrate (the basis of the fruit-juice interaction). (1)
routes:

Showing below up to 34 results in range #1 to #34.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)